[Therapy of dysmenorrhea with prostaglandin synthetase inhibitors: experiences with fluproquazone].
The prostaglandin-synthetase inhibitors fluproquazone and mefenamic acid were evaluated for relief of severe primary and secondary IUD-induced dysmenorrhea in a controlled double-blind cross-over study in 48 patients. Relief of dysmenorrhea was good to excellent in 48.7% of the treated patients and in 22.5% of the controls. This difference is statistically significant. It is concluded that fluproquazone and mefenamic acid are safe and effective in most patients for the relief of primary dysmenorrhea, and that prostaglandin-synthetase inhibitors are a suitable short-term therapy for this syndrome.
D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors; D004412:Dysmenorrhea / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008528:Mefenamic Acid / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use*; D052999:Quinazolinones
D016861:Cyclooxygenase Inhibitors; D004791:Enzyme Inhibitors; D011799:Quinazolines; D052999:Quinazolinones; D008528:Mefenamic Acid; C023491:fluproquazone
Die Therapie der Dysmenorrhöe mit Prostaglandin-Synthetase-Hemmern: Erfahrungen mit Fluproquazone.